Sterling Investment Advisors, Ltd. Nektar Therapeutics Transaction History

Sterling Investment Advisors, Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 26, 2020	SELL	$16.59 - $24.79 $66,360 - $99,160	-4,000 Reduced 87.91%	550 $9,000
Q2 2020 Jul 24, 2020	BUY	$16.86 - $23.44 $64,068 - $89,072	3,800 Added 506.67%	4,550 $105,000
Q3 2019 Oct 15, 2019	BUY	$16.91 - $36.27 $2,536 - $5,440	150 Added 25.0%	750 $14,000
Q1 2019 May 01, 2019	SELL	$31.58 - $46.35 $138,952 - $203,940	-4,400 Reduced 88.0%	600 $20,000
Q4 2018 Jan 18, 2019	BUY	$30.43 - $56.65 $60,860 - $113,300	2,000 Added 66.67%	5,000 $164,000

Q3 2018 Nov 09, 2018	BUY	$46.46 - $68.49 $139,380 - $205,469	3,000 New	3,000 $183,000
Q2 2018 Jul 26, 2018	SELL	$46.25 - $104.45 $46,250 - $104,450	-1,000 Closed	0 $0
Q1 2018 Apr 23, 2018	BUY	$57.4 - $108.44 $57,400 - $108,440	1,000 New	1,000 $106,000
Q4 2017 Jan 29, 2018	SELL	$23.02 - $60.5 $69,060 - $181,500	-3,000 Closed	0 $0
Q2 2017 Aug 09, 2017	BUY	N/A	3,000	3,000 $59,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $231M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Sterling Investment Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Sterling Investment Advisors, Ltd. with notifications on news.